(Q45977986)

PubMed publication ID

19505729

18 December 2017

http://europepmc.org/abstract/MED/19505729

title

Growth-inhibitory effects of four tyrosine kinase inhibitors on neoplastic feline mast cells exhibiting a Kit exon 8 ITD mutation (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6763335&resulttype=core&format=json

12 May 2020

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6763335&resulttype=core&format=json

12 May 2020

Barbara Peter

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6763335&resulttype=core&format=json

12 May 2020

Peter Valent

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6763335&resulttype=core&format=json

12 May 2020

8

Winfried F Pickl

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6763335&resulttype=core&format=json

12 May 2020

5

Karoline V Gleixner

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6763335&resulttype=core&format=json

12 May 2020

7

Tuddow Thaiwong

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6763335&resulttype=core&format=json

12 May 2020

Vilma Yuzbasiyan-Gurkan

9

object named as

Vilma Yuzbasiyan-Gurkan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6763335&resulttype=core&format=json

12 May 2020

3

Laura Rebuzzi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6763335&resulttype=core&format=json

12 May 2020

6

Alexander Gruze

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6763335&resulttype=core&format=json

12 May 2020

author name string

Christian Baumgartner

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6763335&resulttype=core&format=json

12 May 2020

Michael Willmann

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6763335&resulttype=core&format=json

12 May 2020

publication date

18 May 2009

1 reference

PubMed publication ID

19505729

18 December 2017

http://europepmc.org/abstract/MED/19505729

published in

Veterinary Immunology and Immunopathology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6763335&resulttype=core&format=json

12 May 2020

volume

132

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6763335&resulttype=core&format=json

12 May 2020

issue

2-4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6763335&resulttype=core&format=json

12 May 2020

page(s)

243-250

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6763335&resulttype=core&format=json

Identification of basogranulin (BB1) as a novel immunohistochemical marker of basophils in normal bone marrow and patients with myeloproliferative disorders.

12 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

The biology of Kit in disease and the application of pharmacogenetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Splenic mast cell tumour and mastocytaemia in a cat: case study and literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Activating mutations in the catalytic or juxtamembrane domain of c-kit in splenic mast cell tumors of cats.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Prevalence and importance of internal tandem duplications in exons 11 and 12 of c-kit in mast cell tumors of dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

KIT mutations in mastocytosis and their potential as therapeutic targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Systemic mastocytosis in a cat: remission after splenectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Successful treatment of progressive cutaneous mastocytosis with imatinib in a 2-year-old boy carrying a somatic KIT mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Identification of a c-kit exon 8 internal tandem duplication in a feline mast cell tumor case and its favorable response to the tyrosine kinase inhibitor imatinib mesylate.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

A phase I clinical trial evaluating imatinib mesylate (Gleevec) in tumor-bearing cats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Characterisation of the signalment, clinical and survival characteristics of 41 cats with mast cell neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Spontaneous canine mast cell tumors express tandem duplications in the proto-oncogene c-kit

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Mast cells and mastocytosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Cutaneous mast cell tumors in cats: 32 cases (1991-1994).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

C-kit gene product (CD117) immunoreactivity in canine and feline paraffin sections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

A study of mutations in the c-kit gene of 32 dogs with mastocytoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

The riddle of the mast cell: kit(CD117)-ligand as the missing link?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Mastocytosis: pathology, genetics, and current options for therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Morphological and biochemical aspects of apoptosis, oncosis and necrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

Mutations in the juxtamembrane domain of c-KIT are associated with higher grade mast cell tumors in dogs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VETIMM.2009.05.007

7 January 2021

Systemic mastocytosis

1 reference

12 December 2020

Mast cell typing: demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes.

1 reference

12 December 2020

Long-term survival of two cats with mastocytosis

1 reference

12 December 2020

The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others.

1 reference

12 December 2020

10.1016/J.VETIMM.2009.05.007

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6763335&resulttype=core&format=json

12 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6763335&resulttype=core&format=json

12 May 2020

PubMed publication ID

19505729

1 reference